Valthos Industries

About Valthos Industries

Valthos Industries operates at the critical intersection of artificial intelligence and national security, specializing in next-generation biodefense. Founded in 2024 by Kathleen McMahon and Tess van Stekelenburg, the New York-based company is developing a biological intelligence platform to identify and counter emerging biological threats. McMahon, the CEO, previously led the life sciences division at Palantir Technologies, while van Stekelenburg was a computational neuroscience researcher and a venture partner at Lux Capital. The founding team also includes AI engineer Victor Mao from Google DeepMind and specialists from Stanford's Arc Institute and MIT's Broad Institute.

The company's core mission is to address the asymmetry in biodefense, where creating a pathogen is currently easier and faster than developing a cure. Valthos builds frontier AI systems designed to rapidly characterize biological sequences, identify threats in real-time, and compress the timeline for designing medical countermeasures. This software infrastructure aggregates biological data from various commercial and government sources, such as air and wastewater monitoring, and applies AI to detect anomalies and assess risks. The platform aims to shift biodefense from a static response model to a dynamic, adaptive one.

Valthos serves government agencies, public health organizations, and life sciences stakeholders. Its business model appears to be centered on providing its AI-powered biosurveillance platform through government contracts, subscription services, and defense agency licensing. The company also plans to form partnerships with pharmaceutical companies for the manufacturing and distribution of AI-designed countermeasures. In October 2025, Valthos emerged from stealth with $30 million in seed funding from notable investors including the OpenAI Startup Fund, Lux Capital, and Founders Fund, which will be used to scale its software infrastructure and expand its engineering team.